US researchers have found that an inexpensive and rapid testing method can effectively identify a sub-group of never-smoking lung cancer patients whose tumors express a molecule associated with increased risk of disease progression or recurrence.
Approximately 8 percent - 12 percent of patients with lung adenocarcinoma who have never smoked cigarettes carry tumors that express a protein product called anaplastic lymphoma kinase (ALK).
Dr Ping Yang from the Mayo Clinic, Rochester, USA, said, "This subset of patients are at more than double the risk of experiencing disease progression or recurrence within 5 years of initial diagnosis compared to never-smokers whose lung adenocarcinoma tumors are ALK-negative."
Immunohistochemistry tests use antibodies to identify specific proteins in tissue sections; FISH uses fluorescent probes to bind to specific DNA sequences in the chromosomes of individual cells.
In a study of 303 samples, the research team found that immunohistochemistry results correlated well with the results of FISH. Tissue samples with the highest immunohistochemistry scores (IHC 3+) were all FISH positive, while those with no immunohistochemistry staining (IHC 0) were FISH negative.
Based on these findings, only samples that were scored with the intermediate IHC scores of 1+ and 2+ would need confirmatory testing with FISH, Dr Yang explained. "In this particular cohort, IHC score 2+ and 1+ cases represented approximately 27 percent of those screened. Even if confirmatory testing is done on all IHC 2+ and 1+ cases, confirmatory testing could be avoided on roughly three quarters of the cases."
Immunohistochemistry is routinely performed in pathology labs and is a relatively inexpensive and rapid test method. "Because it is already performed in most pathology labs, testing can be done on-site versus sending a sample to another diagnostic testing site. Thus, IHC may be a good initial screening tool for ALK status," Dr Yang explained.
Overall, the researchers found that 8.2-12.2 percent of this never-smoking group with lung adenocarcinoma had tumors that expressed ALK. The ALK positive tumors were significantly more aggressive as measured by tumor grade of differentiation and stage, and were diagnosed in younger patients, Dr Yang said.
However, there are no guidelines or standard protocols for ALK testing by IHC at the present time; proper standardization and validation of IHC procedures for ALK testing are needed, including evaluating the effectiveness of different antibodies, Dr. Yang added.
The findings were reported at the European Multidisciplinary Conference in Thoracic Oncology (EMCTO), 24-26 February 2011, Lugano, Switzerland.